Quantcast

Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
September 21, 2014, 10:33:26 AM

Login with username, password and session length


Members
  • Total Members: 23511
  • Latest: rock
Stats
  • Total Posts: 639643
  • Total Topics: 48551
  • Online Today: 210
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: MazF HIV Gene Therapy  (Read 2698 times)

0 Members and 1 Guest are viewing this topic.

Offline Inchlingblue

  • Member
  • Posts: 3,119
  • Chad Ochocinco PETA Ad
MazF HIV Gene Therapy
« on: March 12, 2010, 10:33:45 AM »
Takara Bio to Enter into a Collaborative Research Agreement with University of Pennsylvania, Aiming for a Future Clinical Trial of HIV Gene Therapy

Tokyo, Mar 12, 2010 (JCN Newswire via COMTEX) -- Takara Bio Inc. announced today that it has executed a collaborative research agreement with University of Pennsylvania on March 11, 2010 to support an HIV gene therapy clinical trial in the United States. Under this agreement, Takara and Carl H. June, MD, professor of Pathology and Laboratory Medicine at the University of Pennsylvania School of Medicine, will jointly conduct pre-clinical translational studies and regulatory steps required for completion of an Investigational New Drug (IND) application to the Food and Drug Administration (FDA).

Takara has been developing a novel technology for HIV gene therapy, in which MazF, an RNA cleavage enzyme from E. coli, is stably delivered to CD4 T cells by retroviral vector. We have demonstrated that human T cells transduced with MazF can significantly inhibit replication of HIV in vitro, while not affecting cell growth. We have also demonstrated a promising result that MazF is similarly effective against multi-drug resistant HIV strains. Animal experiments on the MazF HIV gene therapy using macaques have been undertaken in collaboration with Tsukuba Primate Research Center of National Institute of Biomedical Innovation (Tsukuba, Japan).

Takara aims to launch its first clinical trial of MazF HIV gene therapy in the United States, considering market potential for treatment of HIV, successful achievements in ex vivo gene therapy in the country to date, and possible expansion of the business worldwide after completion of the clinical trial. In the past decade, Professor June has conducted multiple clinical trials for HIV gene therapy in the United States, and therefore he and his team have extensive IND and clinical trial experience.

Under the agreement, Takara and Penn will jointly pursue an IND application, in particular pre-clinical studies including animal tests and GMP manufacturing scale-up, regulatory submission to the Recombinant DNA Advisory Committee of the National Institutes of Health (NIH RAC), pre IND meetings with FDA, and preparation and submission of documents for the IND application. We expect that the IND application will be filed in two years, and a clinical trial in the United States will be launched shortly afterwards.


LINK:

http://www.marketwatch.com/story/takara-bio-to-enter-into-a-collaborative-research-agreement-with-university-of-pennsylvania-aiming-for-a-future-clinical-trial-of-hiv-gene-therapy-2010-03-12?reflink=MW_news_stmp

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.